Verady and Digital Asset Research Partner to Provide Institutional Crypto Asset Financial Reporting

Verady and Digital Asset Research Partner to Provide Institutional Crypto Asset Financial Reporting

/PRNewswire/ — Verady, maker of the Ledgible cryptocurrency tax, accounting, and financial reporting platform, today announced a partnership with Digital… Qualcomm (QCOM) news for Thursday includes its stock gaining after the release of its earnings report for the fiscal fourth quarter of 2020. Several brokerages have updated their recommendations and price targets on shares of Eaton (NYSE: ETN) in the last few weeks: 11/4/2020 – Eaton had its price target raised by analysts at Credit Suisse Group AG from $110.00 to $118.00. They now have an “outperform” rating on the stock. 11/4/2020 – Eaton had its price target […] /PRNewswire/ — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as… The mortgage REIT just gave investors some good news. Aurora Cannabis (ACB) is taking off on Thursday despite no new news from the company as election results continue to pour in.

ATLANTA, Nov. 5, 2020 /PRNewswire/ — Verady, maker of the Ledgible cryptocurrency tax, accounting, and financial reporting platform, today announced a partnership with Digital Asset Research (DAR), the leading cryptoasset data and analytics firm. DAR is the preferred source for institutional level pricing for cryptocurrency market values and will be fully available in Verady’s Ledgible platform for tax, business accounting, and financial reporting. The valuation of cryptoassets can have a significant impact on portfolio accounting and taxes. 

“There are few standards for cryptoasset prices, so we are partnering with Digital Asset Research who clearly leads the market in assessing digital currencies and assets and offers clean prices for our Ledgible clients with institutional requirements,” said Kell Canty, CEO of Verady. “By offering options to our clients, we can give them more ways of finding value and accurately complete the short and long term cryptocurrency activity for the taxpayer.”

DAR provides comprehensive data and research in the digital asset space for institutional market participants with clean crypto prices, market data and independent research. The company offers clean and reliable data through its vetting of assets and exchanges and in-depth analysis on technology, security and market structure.

“Our fundamental understanding of cryptoassets and history in financial markets provides institutional rigor to the cryptocurrency market. Our comprehensive vetting methodologies allow us to identify economic trading between real buyers and sellers in this market in order to accurately price these assets,” said Erin Friez, COO and General Counsel with Digital Asset Research. “Working with Verady and their Ledgible platform brings our pricing and data to customers who need a way to account for their cryptoassets.”

DAR’s objective is to provide transparency to the cryptocurrency space through a comprehensive diligence process, giving market participants access to clean, objective market data, as well as analysis and insight into market structure, price discovery, and other topics of interest to market participants. This includes DAR’s Industry Taxonomy, which organizes over 400 digital assets by use case, underlying technology, and other features, allowing market participants to construct a portfolio around specific themes, to measure performance against other asset classes, or to evaluate risk and exposure. Verady completed its System and Organization Control SOC for its platform used for accounting blockchain transactions. Ledgible integrates with tax and accounting platforms allowing clients and finance professionals to account for Bitcoin and other cryptoassets within accounting systems. Ledgible enables clients to save time and ensure accuracy by consolidating information directly from cryptocurrency data.

About Digital Asset Research
Digital Asset Research provides clean pricing, market data, events calendar and a comprehensive industry taxonomy for crypto assets, as well as research and analysis. DAR is headquartered in New York and provides data and research to institutional clients including investors, asset managers, administrators, custodians, fintech platforms and other financial service customers requiring high quality data and research. DAR is partnered with FTSE Russell for crypto indexes, currently in indicative form.  For more information, please visit digitalassetresearch.com or reach out to [email protected]. 

Media Contact:
Jan Jahosky
[email protected]
407.331.4699

SOURCE Verady

Source: www.prnewswire.com

Author: Verady


Qualcomm News: 5 Things to Know About QCOM Stock Today

Qualcomm News: 5 Things to Know About QCOM Stock Today

Qualcomm (NASDAQ:QCOM) news for Thursday includes QCOM stock on the rise after the release of its earnings report for the fiscal fourth quarter of 2020. That’s thanks to its adjusted earnings per share of $1.45 beating out Wall Street’s estimate of $1.17. Its revenue of $8.35 billion also comes in above analysts’ estimates of $5.93 billion.

Qualcomm (QCOM) logo on the side of a building in San Jose, CA.

Here’s the other positive news from the most recent Qualcomm earnings report.

  • Adjusted per-share earnings are up 86% from 78 cents during the same time last year.
  • Revenue for the quarter is sitting 73% higher than the $4.81 billion reported in fiscal Q4 2019.
  • Operating income of $3.45 billion is a 392.2% increase year-over-year from $701 million.
  • The Qualcomm earnings report also has net income coming in at $2.96 billion.
  • That’s a 485% jump from the company’s net income of $506 million reported in the same period of the year prior.
  • Steve Mollenkopf, CEO of Qualcomm, said the following in the earnings news release.

    “We concluded the year with exceptional fourth quarter results and are well positioned for growth in 2021 and beyond. As the pace of disruption in wireless technology accelerates, we will continue to drive growth and scale across our RF front-end, Automotive and IoT adjacencies.”

    The Qualcomm earnings news also includes guidance for fiscal Q1 2021. It has QCOM expecting adjusted EPS of $1.95 to $2.15 on revenue of $7.8 billion to $8.6 billion. For comparison, Wall Street is looking for adjusted EPS of $1.69 on revenue of $6.58 billion during the quarter.

    QCOM stock was up 13.8% as of Thursday morning.

    On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.

    Article printed from InvestorPlace Media, https://investorplace.com/2020/11/qualcomm-news-boost-qcom-stock-today/.

    ©2020 InvestorPlace Media, LLC

    Source: investorplace.com

    Author: By

    William White, InvestorPlace Writer


    Investment Analysts’ Recent Ratings Updates for Eaton (ETN)

    Investment Analysts’ Recent Ratings Updates for Eaton (ETN)

    Eaton logoSeveral brokerages have updated their recommendations and price targets on shares of Eaton (NYSE: ETN) in the last few weeks:

  • 11/4/2020 – Eaton had its price target raised by analysts at Credit Suisse Group AG from $110.00 to $118.00. They now have an “outperform” rating on the stock.
  • 11/4/2020 – Eaton had its price target raised by analysts at Oppenheimer Holdings Inc. from $110.00 to $118.00. They now have an “outperform” rating on the stock.
  • 11/4/2020 – Eaton had its price target raised by analysts at Morgan Stanley from $104.00 to $113.00. They now have an “equal weight” rating on the stock.
  • 11/4/2020 – Eaton had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $111.00 to $125.00. They now have a “buy” rating on the stock.
  • 10/16/2020 – Eaton had its price target raised by analysts at Citigroup Inc. from $106.00 to $122.00. They now have a “buy” rating on the stock.
  • 10/9/2020 – Eaton had its price target raised by analysts at Wells Fargo & Company from $110.00 to $130.00.
  • NYSE:ETN traded up $3.87 during mid-day trading on Thursday, reaching $109.77. The stock had a trading volume of 51,508 shares, compared to its average volume of 2,427,333. The stock has a market cap of $42.37 billion, a P/E ratio of 29.43, a PEG ratio of 2.49 and a beta of 1.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.50 and a quick ratio of 1.11. The business’s 50 day moving average is $105.04 and its 200 day moving average is $93.77. Eaton Co. plc has a fifty-two week low of $56.42 and a fifty-two week high of $111.99.

    Eaton (NYSE:ETN) last posted its quarterly earnings data on Saturday, November 7th. The industrial products company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.13. Eaton had a return on equity of 12.73% and a net margin of 8.03%. The company had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.21 billion. During the same period in the prior year, the business earned $1.52 earnings per share. Eaton’s revenue for the quarter was down 14.8% compared to the same quarter last year. Equities analysts expect that Eaton Co. plc will post 3.94 EPS for the current year.

    In related news, insider Richard H. Fearon sold 40,550 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $102.01, for a total value of $4,136,505.50. Following the transaction, the insider now owns 151,834 shares in the company, valued at $15,488,586.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Richard H. Fearon sold 50,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $101.98, for a total value of $5,099,000.00. Following the transaction, the insider now owns 150,384 shares in the company, valued at approximately $15,336,160.32. The disclosure for this sale can be found here. Insiders sold 93,597 shares of company stock valued at $9,550,626 over the last 90 days. 0.54% of the stock is currently owned by corporate insiders.

    A number of institutional investors and hedge funds have recently modified their holdings of ETN. NuWave Investment Management LLC bought a new position in Eaton during the second quarter worth about $32,000. Hoover Financial Advisors Inc. bought a new position in shares of Eaton during the 2nd quarter valued at about $33,000. Fiduciary Planning LLC bought a new position in shares of Eaton during the 3rd quarter valued at about $41,000. Rockbridge Investment Management LCC bought a new position in shares of Eaton during the 2nd quarter valued at about $42,000. Finally, Heritage Wealth Advisors raised its position in Eaton by 59.0% in the 2nd quarter. Heritage Wealth Advisors now owns 803 shares of the industrial products company’s stock valued at $44,000 after buying an additional 298 shares during the last quarter. Hedge funds and other institutional investors own 77.55% of the company’s stock.

    Eaton Corporation plc operates as a power management company worldwide. Its Electrical Products segment offers electrical and industrial components, wiring devices, and structural support systems; and residential, single phase power quality, emergency lighting and fire detection, and circuit protection and lighting products.

    Receive News & Ratings for Eaton Co plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eaton Co plc and related companies with MarketBeat.com’s FREE daily email newsletter.

    Source: www.americanbankingnews.com

    Author: ABMN Staff


    Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights

    Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights

    AUSTIN, Texas, Nov. 5, 2020 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today reported its third quarter 2020 financial results, and provided recent corporate and program highlights.

    “Although it’s been a challenging environment for biotech with the global pandemic, we have continued to be productive in our Arginase 1 Deficiency patient identification and engagement efforts. I am pleased with the progress we are making overall as well as specifically at our PEACE trial sites,” said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. “I am also excited by the momentum we are building in our Homocystinuria program with the recent granting of U.S. Orphan Drug Designation and a positive opinion for EU Orphan Drug Designation for ACN00177.”

    Recent Highlights and Updates

    Pegzilarginase in Arginase 1 Deficiency

  • In September, Aeglea announced the PEACE Phase 3 pivotal trial was more than 50% enrolled with nearly twice the number of patients needed to complete enrollment identified at active trial sites. Enrollment for the trial is anticipated to be completed in January 2021.
  • As of September, Aeglea has identified over 250 Arginase 1 Deficiency patients in addressable markets, a 25% increase relative to the prior year. The number of currently identified patients represents more than 50% and 30% of the estimated genetic prevalence populations in the U.S. and EU5, respectively.
  • ACN00177 in Homocystinuria

  • In October, Aeglea announced the U.S. Food and Drug Administration granted Orphan Drug Designation to ACN00177 for the treatment of Homocystinuria.
  • Additionally, the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug Designation for ACN00177 for the treatment of Homocystinuria in the European Union.
  • Corporate

  • In October, the Company strengthened its financial position with proceeds from shares of common stock sold under its ATM program, resulting in gross proceeds of $25 million, extending its cash runway into 2023.
  • Upcoming Events

    Aeglea will be attending the following virtual investor conferences in the fourth quarter:

  • Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3
  • 3rd Annual Evercore ISI HealthCONx Conference, December 1-3
  • Third Quarter 2020 Financial Results

    As of September 30, 2020, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $141.5 million. In addition, in October 2020 the Company raised approximately $24.6 million in net proceeds from shares of common stock sold under its ATM program. Based on Aeglea’s current operating plan, and taking into account the net offering proceeds, management believes it has sufficient capital resources to fund anticipated operations into 2023.

    Research and development expenses totaled $12.5 million for the third quarter of 2020 and $17.8 million for the third quarter of 2019. The decrease was primarily associated with completing certain manufacturing and pre-commercial activities for Aeglea’s lead product candidate, pegzilarginase, completing a Phase 1/2 clinical trial in patients with Arginase 1 Deficiency and closing cancer trials; offset by a ramp-up in manufacturing for ACN00177 in Homocystinuria and higher personnel-related expenses. 

    General and administrative expenses totaled $5.7 million for the third quarter of 2020 and $4.3 million for the third quarter of 2019. This increase was primarily due to ramping-up commercial capabilities and additional facilities to support company growth.

    Net loss totaled $18.0 million and $21.6 million for the third quarter of 2020 and 2019, respectively, with non-cash stock compensation expense of $1.7 million and $1.4 million for the third quarter of 2020 and 2019, respectively.

    About Pegzilarginase in Arginase 1 Deficiency

    Pegzilarginase is an enhanced human arginase that enzymatically lowers levels of the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D), a rare debilitating, progressive disease presenting in childhood with persistent hyperargininemia, spasticity, developmental delay, intellectual disability, seizures and early mortality. Pegzilarginase is intended for use as an enzyme therapy to reduce elevated blood arginine levels in patients with ARG1-D. Aeglea’s Phase 1/2 and Phase 2 open-label extension data for pegzilarginase in patients with ARG1-D demonstrated clinical improvements and sustained lowering of plasma arginine. The Company’s single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction.

    About ACN00177 in Homocystinuria

    Aeglea is developing ACN00177 for the treatment of patients with cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria. Homocysteine accumulation plays a key role in multiple progressive and serious disease-related complications, including thromboembolic vascular events, skeletal abnormalities including severe osteoporosis, developmental delay, intellectual disability, lens dislocation and severe near-sightedness. ACN00177 has been designed as a novel recombinant human enzyme, which degrades the amino acid homocysteine and its related homocystine dimer. With this mechanism, ACN00177 is intended to lower the abnormally high blood levels of homocysteine in patients with Homocystinuria. Preclinical data demonstrated that ACN00177 improved important disease-related abnormalities and survival in a mouse model of Homocystinuria. The Company initiated a Phase 1/2 trial in the second quarter of 2020 and continues patient identification and administrative activities. The timing of first patient dosing in this Phase 1/2 trial will depend on determinations by individual sites as they adjust to impacts from COVID-19. ACN00177 has been granted Orphan Drug Designation by the U.S. FDA and received a positive opinion on Orphan Drug Designation from the European Medicines Agency.

    About Aeglea BioTherapeutics

    Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea’s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

    Safe Harbor / Forward Looking Statements

    This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, the potential addressable markets of the our product candidates and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Financials

    Aeglea BioTherapeutics, Inc.

    Condensed Consolidated Balance Sheets

    (Unaudited)

    (In thousands, except share and per share amounts)

    September 30,

    December 31,

    2020

    2019

    ASSETS

    CURRENT ASSETS

    Cash and cash equivalents

    $

    54,223

    $

    19,253

    Marketable securities

    85,753

    52,696

    Prepaid expenses and other current assets

    4,423

    2,556

    Total current assets

    144,399

    74,505

    Restricted cash

    1,500

    1,500

    Property and equipment, net

    5,216

    2,385

    Operating lease right-of-use assets

    4,394

    4,726

    Other non-current assets

    122

    67

    TOTAL ASSETS

    $

    155,631

    $

    83,183

    LIABILITIES AND STOCKHOLDERS’ EQUITY

    CURRENT LIABILITIES

    Accounts payable

    $

    2,295

    $

    3,154

    Operating lease liabilities

    341

    351

    Accrued and other current liabilities

    11,713

    14,854

    Total current liabilities

    14,349

    18,359

    Non-current operating lease liabilities

    4,947

    4,712

    Other non-current liabilities

    61

    31

    TOTAL LIABILITIES

    19,357

    23,102

    STOCKHOLDERS’ EQUITY

    Preferred stock, $0.0001 par value; 10,000,000 shares authorized
    as of September 30, 2020 and December 31, 2019; no shares issued and
    outstanding as of September 30, 2020 and December 31, 2019

    Common stock, $0.0001 par value; 500,000,000 shares authorized
     as of September 30, 2020 and December 31, 2019; 44,692,030 shares and
     29,084,437 shares issued and outstanding as of September 30, 2020
     and December 31, 2019, respectively

    5

    3

    Additional paid-in capital

    389,543

    255,142

    Accumulated other comprehensive income

    20

    51

    Accumulated deficit

    (253,294)

    (195,115)

    TOTAL STOCKHOLDERS’ EQUITY

    136,274

    60,081

    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

    $

    155,631

    $

    83,183

    Aeglea BioTherapeutics, Inc.

    Condensed Consolidated Statements of Operations

    (Unaudited)

     (In thousands, except share and per share amounts)

    Three Months Ended

    September 30,

    Nine Months Ended

    September 30,

    2020

    2019

    2020

    2019

    Operating expenses:

    Research and development

    12,451

    17,839

    43,882

    47,034

    General and administrative

    5,672

    4,307

    14,823

    11,391

    Total operating expenses

    18,123

    22,146

    58,705

    58,425

    Loss from operations

    (18,123)

    (22,146)

    (58,705)

    (58,425)

    Other income (expense):

    Interest income

    88

    585

    549

    1,711

    Other income (expense), net

    2

    (12)

    (23)

    (45)

    Total other income

    90

    573

    526

    1,666

    Net loss

    $

    (18,033)

    $

    (21,573)

    $

    (58,179)

    $

    (56,759)

    Net loss per share, basic and diluted

    $

    (0.29)

    $

    (0.66)

    $

    (1.18)

    $

    (1.80)

    Weighted-average common shares outstanding, basic and

       diluted

    62,240,412

    32,894,205

    49,473,350

    31,596,321

    SOURCE Aeglea BioTherapeutics, Inc.

    Source: www.prnewswire.com

    Author: Aeglea BioTherapeutics, Inc.


    Here's Why MFA Financial Is Soaring Today

    Here’s Why MFA Financial Is Soaring Today

    The stock market continued its post-election rally on Thursday, with all major market averages higher by at least 2% as of 3:25 p.m. EST. However, mortgage real estate investment trust MFA Financial (NYSE:MFA) was a big outperformer, up by about 6.2% at that point in the trading day after being up by as much as 12% earlier in the session.

    The short explanation for that pop was that MFA’s third-quarter earnings report handily surpassed analysts’ expectations. The mortgage REIT earned $0.17 per share, and while that was less than the $0.20 per share it generated in the same quarter a year ago, it was more than triple the consensus forecast of $0.05 per share.

    Miniature house and calculator sitting next to money with house keys on top.

    Image source: Getty Images.

    More importantly, MFA’s business seems to be stabilizing, and management seems far more confident about the company’s financial position than it was in the second quarter. The company was able to reinstate the dividend on its preferred stock and pay all accrued unpaid amounts. And the company repaid in full the $481 million term loan it took out in June, which significantly lowered its interest expenses.

    At the end of the third quarter, MFA’s book value stood at $4.61 per share, so even after Thursday’s move, the stock — at a price in the neighborhood of $3.10 a share — is still trading for a substantial discount to the value of its assets. MFA CEO Craig Knutson said in the earnings press release that the quarter’s results “were the beginning of what we hope is a return to normal in this tumultuous year of 2020.” If his cautious optimism proves correct, there could be significantly more upside potential for the stock ahead.

    Source: www.fool.com

    Author: Matthew Frankel, CFP


    Aurora Cannabis News: 11 Things to Know About ACB Stock Today

    Aurora Cannabis News: 11 Things to Know About ACB Stock Today

    Aurora Cannabis (NYSE:ACB) is taking off on Thursday despite no new news from the company as election results continue to pour in.

    Aurora Cannabis (ACB) logo on a web page

    Here’s what investors in ACB stock need to know about the Aurora Cannabis news.

  • Presidential candidate Joe Biden has pulled ahead of sitting President Donald Trump in the 2020 elections.
  • That’s good for pot stocks, such as ACB, as Biden’s campaign has been pushing to decriminalize marijuana use at a federal level.
  • On the other hand, President Trump’s campaign hasn’t given much focus to decriminalizing the drug.
  • This is the same reason that many cannabis stocks were falling yesterday as Trump appeared to be in the lead.
  • An expectation to that rule was GW Pharmaceuticals (NASDAQ:GWPH), which was up on strong Q3 earnings results.
  • However, that doesn’t mean the current election results are all good news for Aurora Cannabis and other pot stocks.
  • While Democrats were hoping to take over the Senate this year, it doesn’t look like that’s going to happen.
  • Republicans are currently ahead in the Senate race with 48 seats compared to Democrats’ 47 seats.
  • While Democrats will likely maintain control of the House, it will be difficult to pass new legislation if Republicans continue to hold the Senate.
  • That could spell trouble for lawmakers seeking to decriminalize marijuana in the U.S.
  • Investors will just have to wait until the elections are over for more solid news.
  • ACB stock was up 17.5% as of Thursday morning.

    On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.

    Article printed from InvestorPlace Media, https://investorplace.com/2020/11/aurora-cannabis-news-boosts-acb-stock/.

    ©2020 InvestorPlace Media, LLC

    Source: investorplace.com

    Author: By

    William White, InvestorPlace Writer


    Verady and Digital Asset Research Partner to Provide Institutional Crypto Asset Financial Reporting


    Leave a Comment